Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Frontiers in immunology·2026
Same author

Lynch syndrome integrative epidemiology and genetics (LINEAGE): rationale for cohort design.

Familial cancer·2026
Same author

Phase II trial of encapsulated rapamycin to reduce polyp burden associated with familial adenomatous polyposis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Instability in Pentanucleotide Markers in a Subset of Microsatellite Instability-High Colorectal Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors.

Cancer discovery·2026
Same author

Colorectal Cancer Screening Knowledge and Associated Willingness and Barriers to Screening in Nationwide Pakistan Cohort.

Euroasian journal of hepato-gastroenterology·2026

Related Experiment Video

Updated: Oct 16, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

428

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.

Jennifer M Weiss1, Samir Gupta2, Carol A Burke3

  • 1University of Wisconsin Carbone Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|October 19, 2021
PubMed
Summary

Identifying hereditary cancer syndromes enables early surveillance and risk management. These guidelines focus on assessing colorectal cancer risks, particularly for familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) syndromes.

More Related Videos

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Experiment Videos

Last Updated: Oct 16, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

428
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Area of Science:

  • Oncology
  • Genetics
  • Clinical Guidelines

Background:

  • Hereditary cancer syndromes necessitate specialized surveillance and management strategies.
  • Accurate risk assessment is crucial for identifying individuals with pathogenic genetic variants.
  • The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for high-risk cancer assessment.

Purpose of the Study:

  • To present updated NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.
  • To focus on familial adenomatous polyposis (FAP) and attenuated familial adenomatous polyposis (AFAP) syndromes.
  • To address the management of duodenal neoplasia in at-risk individuals.

Main Methods:

  • Annual review of clinical expertise and new scientific data by the NCCN Genetic/Familial High-Risk Assessment: Colorectal panel.
  • Development and dissemination of evidence-based recommendations for hereditary colorectal cancer syndromes.
  • Focus on specific hereditary cancer syndromes and associated clinical management.

Main Results:

  • Updated recommendations for the assessment and management of patients at risk for high-risk colorectal cancer syndromes.
  • Specific considerations for familial adenomatous polyposis (FAP) and attenuated familial adenomatous polyposis (AFAP) syndromes.
  • Guidance on the management of duodenal neoplasia within the context of these syndromes.

Conclusions:

  • Timely identification of hereditary cancer syndromes improves patient outcomes through surveillance and risk reduction.
  • The NCCN Guidelines offer a framework for consistent and effective management of hereditary colorectal cancer.
  • Updated guidelines ensure clinical practice is informed by the latest scientific advancements and expert consensus.